HC Wainwright Reaffirms “Buy” Rating for Telix Pharmaceuticals (NASDAQ:TLX)

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 64.61% from the company’s previous close.

TLX has been the subject of a number of other research reports. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Monday, April 20th. Wedbush reissued an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a report on Monday. Finally, Wall Street Zen upgraded shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $21.12.

Telix Pharmaceuticals Price Performance

Shares of NASDAQ TLX opened at $12.15 on Tuesday. The stock has a fifty day moving average price of $10.27 and a 200 day moving average price of $8.86. Telix Pharmaceuticals has a 1-year low of $6.28 and a 1-year high of $16.98. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Insider Activity

In other news, CEO Christian Behrenbruch purchased 34,500 shares of the business’s stock in a transaction dated Tuesday, April 28th. The stock was acquired at an average price of $14.48 per share, with a total value of $499,560.00. Following the purchase, the chief executive officer directly owned 20,709,500 shares of the company’s stock, valued at $299,873,560. This represents a 0.17% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Hedge Funds Weigh In On Telix Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers lifted its holdings in shares of Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after purchasing an additional 1,392 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Telix Pharmaceuticals during the 4th quarter worth approximately $89,000. Bank of America Corp DE raised its position in shares of Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after purchasing an additional 8,423 shares during the last quarter. OLD Mission Capital LLC purchased a new stake in Telix Pharmaceuticals in the 4th quarter valued at approximately $111,000. Finally, XY Capital Ltd purchased a new stake in Telix Pharmaceuticals in the 1st quarter valued at approximately $120,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.